Vicarious Surgical (RBOT) Form 144 Reports Restricted Stock Lapse and Proposed Sale
Rhea-AI Filing Summary
Vicarious Surgical Inc. (RBOT) filing is a Form 144 notice reporting proposed sales of Class A common stock by an insider. The filing lists a planned sale of 653 shares through UBS Financial Services with an aggregate market value of $4,166.14 and an approximate sale date of 08/20/2025 on the NYSE. The securities were acquired on 08/19/2025 by restricted stock lapse, showing 1,902 shares acquired in that transaction. The filer also disclosed three prior sales in the past three months totaling 1,115 shares with gross proceeds of $8,039 on 05/20/2025, 06/03/2025, and 06/23/2025. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider notice of small proposed sale following restricted stock lapse; transaction size appears immaterial to shareholders.
The Form 144 documents a proposed sale of 653 Class A shares valued at $4,166.14 to be executed through UBS on the NYSE after a restricted stock lapse dated 08/19/2025. Recent sales in May and June totaled 1,115 shares for $8,039, indicating ongoing disposition of small holdings rather than a single large liquidation. For investors, these filings are compliance disclosures and do not, by themselves, provide evidence of material company-level events.
TL;DR: Compliance-focused disclosure showing insider adherence to Rule 144 procedures following restriction lapse.
The notice includes required information about acquisition method (restricted stock lapse) and aggregation of prior sales within three months, meeting Rule 144 reporting obligations. The representation that no undisclosed material adverse information is known is included. From a governance perspective, this appears procedural and consistent with expected insider reporting post-vesting.